eCOA Growth Phase IV White Paper 

Regulatory approval alone no longer guarantees market access or reimbursement. Pharmaceutical companies must demonstrate real-world relative effectiveness to satisfy payers, providers, and patient advocacy groups.

This white paper examines how prospective Phase IV studies and electronic Patient Reported Outcomes (ePRO) bridge the gap between clinical efficacy and real-world value.

Key Topics Covered:

• Navigating Market Access: Shift from volume-based to outcome-based reimbursement models.
• Capturing Real-World Evidence (RWE): Reduce recall bias and measure true quality-of-life impact using ePRO.
• Wearables & Virtualisation: Combine subjective ePRO data with objective sensor data for deeper patient insights.
• Improving Adherence: Address behavioral obstacles and patient burden to improve long-term treatment outcomes.

Download the whitepaper to learn more